Revenue
2022
2023
2024
2025
Transcode Therapeutics, Inc. (RNAZ)
Price$2.06Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $13.4M | $9.7M | $12.3M | $10.2M | $2.8M | $284,459 |
| Operating expenses | $28.0M | $15.7M | $19.4M | $18.6M | $6.2M | $726,604 |
| Operating income | −$28.0M | −$15.7M | −$19.4M | −$18.6M | −$6.2M | −$726,604 |
| EBITDA | −$27.9M | −$15.6M | −$19.3M | −$18.5M | −$6.1M | −$726,604 |
| Net income | −$34.7M | −$16.8M | −$18.5M | −$17.6M | −$6.8M | −$2.3M |
| Basic EPSper basic share | -$52.59 | -$1,336.63 | -$95,770.59 | -$887,394,957,983.19 | -$532,436,974,789.92 | -$335,238,095,238.10 |
| Diluted EPSper diluted share | -$52.59 | -$1,336.63 | -$95,770.59 | -$887,394,957,983.19 | -$532,436,974,789.92 | -$335,238,095,238.10 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Yorkville Advisors Global, LP | 19.64K |
VANGUARD CAPITAL MANAGEMENT LLC | 6.55K |
VANGUARD FIDUCIARY TRUST CO | 2.98K |
UBS Group AG | 2.89K |
FMR LLC | 706 |
Tower Research Capital LLC (TRC) | 677 |
WELLS FARGO & COMPANY/MN | 55 |
SBI Securities Co., Ltd. | 12 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data